Sci-Tech Today: Africa
SEE OTHER BRANDS

Get your science and technology news from Africa

Sci-Tech Today: Africa: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Today: Africa.

Press releases published on April 7, 2025

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of …

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …

Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development

Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development

ANN ARBOR, Mich., April 07, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk-based super materials, is pleased to announce the appointment of Dr. Xiaoli Zhang as Director of …

Shoals Technologies Group, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call

Shoals Technologies Group, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call

PORTLAND, Tenn., April 07, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its first quarter 2025 results before market open on Tuesday, May 6, 2025, to be followed by a …

Atwater Brewery Releases Atwater Light: Detroit’s Premium Light Craft Beer

Atwater Brewery Releases Atwater Light: Detroit’s Premium Light Craft Beer

DETROIT, April 07, 2025 (GLOBE NEWSWIRE) -- Atwater Brewing, Detroit’s renowned craft brewery and a craft beer brand of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch of Atwater Light, a low-calorie, low-carb addition …

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia …

ADMA Biologics Statement on Tariffs

ADMA Biologics Statement on Tariffs

RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics …

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows …

 LG U+ Uses Denodo Platform to Build Modern, Integrated Data Management Infrastructure

LG U+ Uses Denodo Platform to Build Modern, Integrated Data Management Infrastructure

SEOUL, South Korea, April 07, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced that it will provide its logical data management solution, the Denodo Platform, to LG U+, the mobile operator division of LG and the second-largest …

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years …

Update on Extraordinary General Meeting – Extension of Zijin Put Option and Exclusivity Arrangements

Update on Extraordinary General Meeting – Extension of Zijin Put Option and Exclusivity Arrangements

TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) refers to its announcement dated 12 March 2025 in relation to an Extraordinary General Meeting (EGM) to be held on Friday, 11 April 2025. The EGM …

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for …

Holding(s) in Company

Holding(s) in Company

Reykjavík, April 07, 2025 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   1a. Identity of the issuer or the …

Telix Appoints Paul Schaffer as Chief Technology Officer

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology …

Wesdome Gold Mines to Acquire Angus Gold; Quadruples the Eagle River Land Package

Wesdome Gold Mines to Acquire Angus Gold; Quadruples the Eagle River Land Package

All amounts are expressed in Canadian dollars unless otherwise indicated TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) (“Wesdome” or the “Company”) and Angus Gold Inc. (TSX-V: GUS, OTC: ANGVF) (“Angus”) are …

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …

Jitterbit Earns 20 G2 Spring 2025 Badges for Leadership in Enterprise Automation, Integration and App Development

Jitterbit Earns 20 G2 Spring 2025 Badges for Leadership in Enterprise Automation, Integration and App Development

ALAMEDA, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, today announced its Harmony platform has been recognized as a leader by G2, the world's largest and most trusted …

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All …

ExoraPad Presale Surges Past 70,000 XRP Raised, Set For DEX Launch and Launchpad Prototype Release in Q2 2025

ExoraPad Presale Surges Past 70,000 XRP Raised, Set For DEX Launch and Launchpad Prototype Release in Q2 2025

CORK, Ireland, April 07, 2025 (GLOBE NEWSWIRE) -- The excitement within the XRP community is hitting new highs as the ExoraPad presale explodes, crossing a remarkable milestone of 70,000 XRP raised. XRP enthusiasts and seasoned crypto investors, fresh from …

Trident Deepens Partnership with Democratic Republic of Congo for Digital Identity System

Trident Deepens Partnership with Democratic Republic of Congo for Digital Identity System

SINGAPORE, April 07, 2025 (GLOBE NEWSWIRE) -- Trident Digital Tech Holdings Ltd (NASDAQ: TDTH) (“Trident” or the “Company”), a Singapore-based leader in digital transformation, technology optimization, and Web 3.0 activation, today announced progress in …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service